BioPharm 国际生物医药展规模再攀高峰

  • BioPharm,生物医药,医药展,医药界
  • 生物探索

近年来,我国生物医药行业不断发展,从整体状况看,绝大多数生产企业都在努力向GMP靠拢。生物医药属于新兴高技术行业,在全球范围内正处于快速增长期。我国生物医药产业起步较晚,尚处于发展阶段,发展空间巨大。有鉴于此,由国际医药资源网、PI《医药界》杂志发起,HNZ MEDIA 鸿与智商业媒体和UTM-GLOBAL共同主办的「BioPharm 国际生物医药展」(2014中国国际生物医药暨技术设备展览会)将于2014年12月23-25日在上海世博展览馆盛大开幕!

作为亚洲最具影响力的生物医药领域盛会,「BioPharm 国际生物医药展」致力于从产业角度出发,为业界人士提供最新行业资讯及优质的贸易一体化解决方案,积极推动中西方医药企业之间的合作共赢。

本届展会将有超过15个国家和地区的200多家参展商汇聚于此,全面展示生物医药、仪器设备、耗材、试剂、抗体、技术与服务、成果展示等最新科技。超过17,000平方米的展区、100 多家行业合作媒体、10,000 名国内外各大药厂的专业观众组成超强阵容,更有豪华"买家团参观团"的积极参与,带您全面了解2014国际国际生物医药行业的发展态势。

「BioPharm 国际生物医药展」充分利用专业展和贸易展相融合的模式,致力于为业内各领域的公司提供展示新产品和服务的国际化舞台,打造中国生物医药行业的顶级商贸平台。

展会同期,主办方还将专设多场精彩活动,从生物医药行业发展论坛,到最新生物医药企业贸易配对会,再到万众期待的「PI TOP 100 」2014医药行业创新力评选100强榜单发布及颁奖典礼, 旨在向业界展示最新的生物医药技术设备,构建企业展示平台的同时关注用户与买家,为市场提供合作贸易的最佳空间。相信届时展会一定能为大家带来一场高规格、高水平、高质量的生物医药盛会,

想要体验世界顶级医药展览会的精彩纷呈吗?12月23日「BioPharm 国际生物医药展」与您相约上海,让今年冬天火热起来!

This link:

The ChemCD compiler finishing, shall not be reproduced without permission, for reprint please indicate the source。

comments powered by Disqus


Related News

Prime Therapeutics urges FDA to keep current, consistent naming conventions for biologics, biosimilars

Prime Therapeutics, LLC (Prime) has submitted comments to the U.S. Food and Drug Administration (FDA) in support of two citizen petitions on the naming of biosimilar drugs. Biosimilars are medically equivalent versions of biologics, used to treat complex illnesses such as cancer.

FDA Approves Pembrolizumab for Advanced Melanoma

Today the FDA approved Keytruda (pembrolizumab), a new treatment for advanced melanoma, the deadliest form of skin cancer. Melanoma patients have been waiting anxiously for this day, given the promising data that early studies have shown.

Epoxy Resin Market Worth $9.2 Billion by 2019

"Epoxy Resin market by Application (Coatings, Electronics, Construction, Wind Turbine, Composites, and Adhesives) and Geography - Trends & Forecast to 2019" by MarketsandMarkets, the market of epoxy resin is projected to grow from an estimated $5,995.8 million in 2013 to $9,219.1 million by 2019, with a CAGR of 7.4% between 2014 and 2019.

GSK receives FDA approval of an additional Promacta (eltrombopag) indication for use in patients with severe aplastic anaemia (SAA) who have had an insufficient response to immunosuppressive therapy (IST)

FDA has approved a supplemental New Drug Application (sNDA) for the once-daily use of Promacta(eltrombopag) in patients with severe aplastic anaemia (SAA) who have had an insufficient response to immunosuppressive therapy (IST).

FDA Approves The Medicines Company's ORBACTIV™ (oritavancin) for Use in Acute Bacterial Skin and Skin Structure Infections

FDA Approves The Medicines Company's ORBACTIV? (oritavancin) for Use in Acute Bacterial Skin and Skin Structure Infections First and Only Single Dose Antibiotic for the Treatment of Skin Infections Caused by Susceptible Designated Gram-positive Bacteria ORBACTIV?U.S. Launch Expected in 2H/2014

AstraZeneca and QIAGEN enter collaboration to develop diagnostic test for lung cancer patients suitable for treatment with IRESSA

AstraZeneca today announced that it has entered into a collaboration with Netherlands-based QIAGEN to develop a non-invasive diagnostic test to identify non-small cell lung cancer (NSCLC) patients who are suitable for treatment with IRESSA?.

Scientists test nanoparticle 'alarm clock' to awaken immune systems put to sleep by cancer

Researchers at Dartmouth-Hitchcock Norris Cotton Cancer Center are exploring ways to wake up the immune system so it recognizes and attacks invading cancer cells. Tumors protect themselves by tricking the immune system into accepting everything as normal, even while cancer cells are dividing and spreading.